ACADIA Pharmaceuticals Inc (NAS:ACAD)
$ 16.95 -0.42 (-2.42%) Market Cap: 2.89 Bil Enterprise Value: 2.37 Bil PE Ratio: 22.27 PB Ratio: 5.01 GF Score: 75/100

ACADIA Pharmaceuticals Inc at RBC Capital Markets Global Healthcare Conference (Virtual) Transcript

May 18, 2021 / 07:05PM GMT
Release Date Price: $21.39 (+0.75%)
Gregory James Renza
RBC Capital Markets, Research Division - Analyst

RBC Global Healthcare Conference. My name is Greg Renza, one of the senior biotechnology equity research analysts here at RBC, and we're pleased to have ACADIA Pharmaceuticals with us today. And joining us from the team is Steve Davis, Chief Executive Officer; Serge Stankovic, President; and Elena Ridloff, the VP and Chief Financial Officer.

And just some housekeeping before we do get started. If you do have any questions for the team, please feel free to enter those in the web portal below, and we would be happy to ask those on your behalf.

So let's get started. Steve, over to you. Thank you for joining us. And perhaps we can just start by allowing you to provide an overview of ACADIA.

Stephen R. Davis
ACADIA Pharmaceuticals Inc. - CEO & Director

Yes. Great. Thanks much, Greg. Look forward to just doing a little bit of a quick level setting here, and then we'll get right to the Q&A.

So I'd like to just start by highlighting the 3 strategic pillars of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot